France Dry Age-Related Macular Degeneration (AMD) Market Research Report By Stage (Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, Late Age-Related Macular Degeneration), By Age Group (Above 75 years, Above 60 years, Above 40 years), By Diagnosis and Treatment (Treatment, Diagnosis), By Route of Administration (Oral, Injectables) and By End Users (Hospitals Clinics, Diagnostic Centers, Academic Research Institutes) - Forecast to 2035

France Dry Age-Related Macular Degeneration (AMD) Market Overview

As per MRFR analysis, the France Dry Age-Related Macular Degeneration (AMD) Market Size was estimated at 187.0 (USD Million) in 2023. The France Dry Age-Related Macular Degeneration (AMD) Market Industry is expected to grow from 204.0(USD Million) in 2024 to 487.0 (USD Million) by 2035. The France Dry Age-Related Macular Degeneration (AMD) Market CAGR (growth rate) is expected to be around 8.232% during the forecast period (2025 - 2035).

Key France Dry Age-Related Macular Degeneration (AMD) Market Trends Highlighted

In France, the Dry Age-Related Macular Degeneration (AMD) market is witnessing significant trends driven by an aging population and increasing awareness of eye health. The French government has acknowledged the growing prevalence of AMD, which is one of the leading causes of visual impairment among older adults. With nearly a quarter of the population projected to be over 60 by 2030, this demographic shift is pushing healthcare providers and stakeholders to focus on effective AMD management and care solutions. 

The healthcare system in France, known for its universal coverage, is adapting to address the needs of those affected by this condition, including expanded access to ophthalmological care and preventive strategies.The evolving treatment options and new technologies, such as telemedicine, are creating opportunities in the French market. Telemedicine is enhancing access to physician consultations, especially in rural areas. Emerging therapies, including nutraceuticals and drug treatments, are also becoming popular as patients look for ways to manage their condition. In addition, collaboration among pharmaceutical companies and research institutions is increasing in France for the development of more effective treatment modalities and clinical trials, which could foster better patient outcomes. Recently, there has been an observable shift towards supporting and educating patients in France.

As the understanding of AMD becomes more widespread, initiatives focusing on lifestyle modifications and diet are being promoted to help reduce the risk of progression. Eye health screenings are becoming more routine, with the government actively encouraging regular check-ups. This increasing emphasis on proactive health management, along with government support for AMD research, signifies a dynamic shift in how AMD is viewed and treated in France, paving the way for future progress in this market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

France Dry Age-Related Macular Degeneration (AMD) Market Drivers

Increasing Aging Population in France

The aging population in France is a significant driver for the France Dry Age-Related Macular Degeneration (AMD) Market Industry. According to the French National Institute of Statistics and Economic Studies, the proportion of people aged 65 and older in France is projected to rise from 18% in 2020 to around 23% by 2030. This demographic shift focuses the health system on age-related conditions, including AMD, which primarily affects older adults.Increased public awareness campaigns led by organizations like France Retinopathies reinforce the need for treatment and management of AMD, pushing the market's growth as healthcare services respond to the rising patient population. Such a growing demographic indicates an increasing demand for therapies and technologies catering to AMD, making it a pivotal market driver.

Advancements in AMD Treatment Technologies

Technological advancements in the treatment and management of Dry Age-Related Macular Degeneration (AMD) are propelling the France Dry Age-Related Macular Degeneration (AMD) Market Industry forward. Innovative treatments, such as new-generation anti-VEGF therapies and gene therapies, have shown promising results in clinical trials and are gaining traction in administrative health bodies. The French Ministry of Health has been actively promoting research and development in ocular treatments through funding programs, enabling faster patient access to advanced therapies.As a result, the market is expected to witness increased investments, driving overall growth. With 25 new drugs expected to be authorized for AMD in the coming years, there is significant optimism for enhanced treatment outcomes.

Rising Awareness and Screening Programs for AMD

The rising awareness and comprehensive screening programs for Dry Age-Related Macular Degeneration (AMD) are significantly influencing the France Dry Age-Related Macular Degeneration (AMD) Market Industry. Various health campaigns, such as those launched by the French Ophthalmology Society, emphasize the importance of early detection and lifestyle modifications to mitigate AMD risks. By advocating for regular eye examinations, these initiatives are leading to higher rates of diagnosis, which in turn drives demand for treatment options.A reported increase in AMD diagnoses by approximately 30% over five years correlates with these awareness efforts, showing a direct effect on market growth as more patients seek therapeutic interventions.

Government Initiatives to Enhance Eye Care Accessibility

Government initiatives in France aimed at enhancing accessibility to eye care services play a crucial role in the growth prospects of the France Dry Age-Related Macular Degeneration (AMD) Market Industry. The French government, through its National Health Strategy, recognizes the urgency of addressing visual impairments as a significant health issue and has thus invested in subsidizing eye care services for lower-income populations. This inclusive approach is expected to significantly increase the number of patients receiving care for AMD, as evidenced by a projected 15% rise in the number of funded eye care appointments by 2025.Such government backing underscores potential market growth by creating access points for patients who may otherwise neglect their AMD symptoms.

France Dry Age-Related Macular Degeneration (AMD) Market Segment Insights

Dry Age-Related Macular Degeneration (AMD) Market Stage Insights

The France Dry Age-Related Macular Degeneration (AMD) Market, particularly within the Stage segment, plays a crucial role in understanding the progression and treatment of this condition. The market is characterized by three primary stages of AMD: early age-related macular degeneration, intermediate age-related macular degeneration, and late age-related macular degeneration. Early age-related macular degeneration is often the most common stage, where patients may not experience significant vision loss, but there is a growing awareness about the importance of early detection and lifestyle interventions to prevent progression.

This stage primarily attracts the attention of healthcare providers as educational campaigns and screening programs aim to address risk factors such as smoking, obesity, and diet. Intermediate age-related macular degeneration represents a stage where patients begin to experience noticeable changes in vision, making monitoring and appropriate management essential to mitigate risks. This stage is essential for identifying patients who may transition to the more severe late age-related macular degeneration stage, which significantly impacts daily activities.Late age-related macular degeneration is marked by severe vision impairment and poses substantial challenges to patients' quality of life, making it a focal point for innovative treatments and healthcare strategies. 

The progress of treatments in the France Dry Age-Related Macular Degeneration (AMD) Market has sparked increased interest from both pharmaceutical companies and healthcare providers, leading to the development of novel therapies aimed at managing symptoms and slowing disease progression across all stages. The segmentation of these stages not only aids in targeted research and healthcare initiatives but also helps in understanding market growth dynamics as more individuals enter the aging population in France, which, according to statistics, is on the rise.With the shift towards preventive care and the emphasis on early diagnosis, the France Dry Age-Related Macular Degeneration (AMD) Market segmentation becomes increasingly important, guiding both public health strategies and clinical practices in addressing this common age-related condition.

As the healthcare ecosystem in France continues to evolve, the focus on each stage within this segment underscores the importance of tailored approaches and interventional strategies to improve outcomes for patients across the spectrum of age-related macular degeneration.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Dry Age-Related Macular Degeneration (AMD) Market Age Group Insights

The France Dry Age-Related Macular Degeneration (AMD) Market is significantly influenced by the Age Group of its population, particularly focusing on individuals over the age of 40, with heightened prevalence in those above 60 and 75 years. The aging population in France contributes to a rising incidence of AMD, which is largely driven by lifestyle factors, dietary habits, and increased life expectancy. Those above 75 years, often faced with multiple health issues, are particularly vulnerable to AMD, emphasizing the need for targeted healthcare services and interventions.This age group holds a substantial share of the market, as a significant number of individuals experience vision impairment or loss associated with this condition. 

The group aged over 60 years also experiences a noticeable impact, with many individuals becoming increasingly aware of preventive measures and treatments for AMD, thus creating a substantial opportunity for various market players. The market reflects a growing trend for innovative therapies and solutions to address AMD, especially among older demographics, signaling a surge in demand for specialized products and services tailored to these age groups, thereby impacting France Dry Age-Related Macular Degeneration (AMD) Market data significantly.

Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Insights

The Diagnosis and Treatment segment of the France Dry Age-Related Macular Degeneration (AMD) Market plays a crucial role in the management of this ocular condition, which affects a significant portion of the elderly population in France. Given that the incidence of AMD is increasing with an aging demographic, effective diagnosis and treatment options are essential. Diagnosis often includes advanced imaging techniques that facilitate early detection, thus improving treatment outcomes. 

The treatment landscape is evolving, with various therapeutic approaches catering to the needs of patients.This segment tends to dominate due to the necessity of timely interventions to slow disease progression and preserve vision, which is vital for maintaining the quality of life for affected individuals. Numerous innovations in treatment protocols, alongside ongoing research, are expected to drive advancements further in this area. The landscape is supported by health policies emphasizing preventive care and access to ophthalmological services, aligning with France's commitment to improving its healthcare system and addressing age-related diseases.Overall, the Diagnosis and Treatment segment represents a critical aspect of the France Dry Age-Related Macular Degeneration (AMD) Market, positioning itself as a significant contributor to market growth and advancements in patient care.

Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Insights

The Route of Administration segment in the France Dry Age-Related Macular Degeneration (AMD) Market is critical as it significantly influences treatment options and patient adherence. This market comprises various methods, prominently featuring oral and injectable forms of therapy. Oral medications offer convenience and ease of use, potentially enhancing patient compliance due to their non-invasive nature. Conversely, injectables, which are essential for delivering precise doses directly into the eye, underscore their importance in managing more severe forms of AMD effectively.The injectables are often favored in clinical practice for their rapid action and effectiveness in controlling disease progression, thus holding a substantial share within the market landscape.

 Moreover, the increasing prevalence of AMD in the aging population in France, largely due to lifestyle factors and demographic shifts, accentuates the demand for innovative treatment methods across various routes of administration. Accessibility to advanced treatment is further supported by the healthcare infrastructure in France, which emphasizes the significance of both oral and injectable routes in delivering efficient and effective AMD care.Overall, the diversity in the Route of Administration reflects the evolving landscape of therapeutic strategies being employed to combat this pervasive condition.

Dry Age-Related Macular Degeneration (AMD) Market End Users Insights

The France Dry Age-Related Macular Degeneration (AMD) Market's End Users segment plays a vital role in shaping the healthcare landscape, primarily comprising hospitals and clinics, diagnostic centers, and academic and research institutes. Hospitals and clinics are essential in diagnosing and managing AMD, often serving as the first point of contact for patients experiencing vision problems. This accessibility fosters early diagnosis and treatment, which is crucial in mitigating the impact of AMD on patients' lives. Diagnostic centers contribute significantly by providing specialized testing and imaging services, which enhance the accuracy of AMD diagnoses, thereby aiding in tailored treatment strategies.Academic and research institutes are critical as they drive advancements in understanding Dry AMD, exploring novel therapeutic options, and training the next generation of professionals in ophthalmology. 

These facilities not only support clinical practices but also play an influential role in policy-making and healthcare improvements concerning age-related eye diseases. The interconnectedness of these End Users showcases their collective importance in addressing the growing prevalence of AMD within the aging population of France. With the demographics indicating a rising trend in elderly individuals, the End Users segment is positioned to be increasingly significant in providing comprehensive care and innovative solutions for AMD management.

France Dry Age-Related Macular Degeneration (AMD) Market Key Players and Competitive Insights

The France Dry Age-Related Macular Degeneration (AMD) Market is characterized by a dynamic competitive landscape driven by advancements in treatment options and a growing patient population. As the prevalence of dry AMD increases due to the aging demographic, various companies are striving to capture market share through innovative therapies, strategic partnerships, and extensive research. The competitive insights within this market reveal a focus on clinical development, regulatory approvals, and the integration of technology to improve patient outcomes. Manufacturers are also increasingly emphasizing the importance of education and awareness around age-related eye conditions to enhance patient engagement and promote timely diagnosis.Bayer has established a significant presence in the France Dry Age-Related Macular Degeneration (AMD) Market, leveraging its expertise in ophthalmology and a robust portfolio of treatments. 

The company has invested heavily in research and development, leading to the introduction of effective therapies aimed specifically at managing the symptoms and progression of dry AMD. Bayer's strengths lie in its strong brand recognition, an extensive distribution network, and collaborations with healthcare professionals to ensure optimal delivery of care. Furthermore, Bayer’s commitment to innovation has led to the exploration of combination therapies, enhancing its competitive edge in the French market.Genentech, a key player in the France Dry Age-Related Macular Degeneration (AMD) Market, focuses on offering cutting-edge treatments and solutions specifically designed for AMD patients. 

The company is known for its innovations in monoclonal antibodies and has successfully developed products that target underlying disease mechanisms. Genentech has a significant market presence in France and is recognized for its efforts in clinical research and patient support initiatives. Its collaborative approach leads to mergers and acquisitions that expand its capabilities, contributing to an enhanced product line. With a strong emphasis on patient education and access to therapies, Genentech’s strengths include its reputation for high-quality treatments and a solid pipeline of future developments, positioning it favorably in the competitive landscape of dry AMD management in France.

Key Companies in the France Dry Age-Related Macular Degeneration (AMD) Market Include:

• Bayer


• Genentech


• Hoya Corporation


• Paragon Biosciences


• Bausch Health


• Zeiss


• Roche


• Pfizer


• Sanofi


• Novartis


• Santen Pharmaceutical


• Alimera Sciences


• AstraZeneca


• Regeneron Pharmaceuticals

France Dry Age-Related Macular Degeneration (AMD) Market Industry Developments

Recent developments in the France Dry Age-Related Macular Degeneration (AMD) Market have shown significant progress from leading companies such as Bayer, Genentech, and Novartis. In September 2023, Genentech received approval in France for a new treatment indication for AMD, reflecting an increase in innovative therapies targeting this condition. Bayer has also been actively enhancing its AMD treatment portfolio through collaborations and research initiatives. 

The market saw substantial growth, with an estimated valuation surge spurred by the aging population in France, which has created a rising demand for effective AMD therapies. Furthermore, important acquisitions have occurred, including Bausch Health's strategic partnership with Santen Pharmaceutical in July 2023 to develop complementary therapies for AMD, which could strengthen its market position. The French government remains focused on eye health initiatives, emphasizing regular screenings and awareness campaigns to improve early detection of AMD. 

This is crucial as the number of individuals affected by dry AMD is expected to increase significantly in the coming years, urging companies like Regeneron Pharmaceuticals and AstraZeneca to expand their research efforts in this area to meet evolving patient needs.

France Dry Age-Related Macular Degeneration (AMD) Market Segmentation Insights

• Dry Age-Related Macular Degeneration (AMD) Market Stage Outlook
  
  
  
  • Early Age-Related Macular Degeneration
  
  
  • Intermediate Age-Related Macular Degeneration
  
  
  • Late Age-Related Macular Degeneration
  
  
  
  

• Dry Age-Related Macular Degeneration (AMD) Market Age Group Outlook
  
  
  
  • Above 75 years
  
  
  • Above 60 years
  
  
  • Above 40 years
  
  
  
  

• Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Outlook
  
  
  
  • Treatment
  
  
  • Diagnosis
  
  
  
  

• Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Outlook
  
  
  
  • Oral
  
  
  • Injectables
  
  
  
  

• Dry Age-Related Macular Degeneration (AMD) Market End Users Outlook
  
  
  
  • Hospitals Clinics
  
  
  • Diagnostic Centers
  
  
  • Academic Research Institutes
  
  
  
  

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	187.0(USD Million)
MARKET SIZE 2024	204.0(USD Million)
MARKET SIZE 2035	487.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	8.232% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Bayer, Genentech, Hoya Corporation, Paragon Biosciences, Bausch Health, Zeiss, Roche, Pfizer, Sanofi, Novartis, Santen Pharmaceutical, Alimera Sciences, AstraZeneca, Regeneron Pharmaceuticals
SEGMENTS COVERED	Stage, Age Group, Diagnosis and Treatment, Route of Administration, End Users
KEY MARKET OPPORTUNITIES	Innovative treatment development, Telemedicine integration, Early diagnosis technologies, Patient education programs, Government-funded healthcare initiatives
KEY MARKET DYNAMICS	Aging population prevalence, Increasing healthcare expenditure, Advancements in treatment options, Growing awareness campaigns, Rising number of clinical trials
COUNTRIES COVERED	France